Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Combined Treatment of Aripiprazole and Escitalopram Oxalate Therapy to Treat Major Depressive Disorders


Affiliations
1 Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, India
     

   Subscribe/Renew Journal


This review article presents the pharmacology of combined treatment of Aripiprazole and Escitalopram oxalate in treatment of Major Depressive Disorders. Aripiprazole is anti psychotic agent. Escitalopram Oxalate is also an antidepressant agent (Selective Serotonin Reuptake Inhibitor). Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia. Escitalopram Oxalate is selective serotonin reuptake inhibitors (SSRIs) are a group of chemically diverse antidepressant drugs that specifically inhibit serotonin reuptake. The SSRIs block the reuptake of serotonin, leading to increased concentrations of the neurotransmitter in the synaptic cleft and, ultimately, to greater postsynaptic neuronal activity. The combination of both have decrease dose and improve Depression. Combination of both the drugs were approved by us government and has been used in Major Depressive Disorders. The main objective of this review article is to provide pharmacological information of combined therapy of of Aripiprazole and Escitalopram Oxalate to researcher in development of combined dosage form of this.

Keywords

Aripiprazole, Escitalopram Oxalate, Major Depressive Disorders, Pharmacology.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 56

PDF Views: 2




  • Combined Treatment of Aripiprazole and Escitalopram Oxalate Therapy to Treat Major Depressive Disorders

Abstract Views: 56  |  PDF Views: 2

Authors

K. Solanki Divya
Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, India
Hasumati Raj
Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, India
Prajapati Neelam
Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, India

Abstract


This review article presents the pharmacology of combined treatment of Aripiprazole and Escitalopram oxalate in treatment of Major Depressive Disorders. Aripiprazole is anti psychotic agent. Escitalopram Oxalate is also an antidepressant agent (Selective Serotonin Reuptake Inhibitor). Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia. Escitalopram Oxalate is selective serotonin reuptake inhibitors (SSRIs) are a group of chemically diverse antidepressant drugs that specifically inhibit serotonin reuptake. The SSRIs block the reuptake of serotonin, leading to increased concentrations of the neurotransmitter in the synaptic cleft and, ultimately, to greater postsynaptic neuronal activity. The combination of both have decrease dose and improve Depression. Combination of both the drugs were approved by us government and has been used in Major Depressive Disorders. The main objective of this review article is to provide pharmacological information of combined therapy of of Aripiprazole and Escitalopram Oxalate to researcher in development of combined dosage form of this.

Keywords


Aripiprazole, Escitalopram Oxalate, Major Depressive Disorders, Pharmacology.